AngioDynamics appoints president and CEO; MDMA announces new VP and general counsel; Wright Medical chief operating officer resigns; and more personnel news from around the industry.

New approaches to cancer immunotherapy promise to change the face of cancer care in a way that will reverberate through the field for years to come. In this issue, we profile Borean Pharma, OncoMed Pharmaceuticals and Receptor Logic.

It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.

The (literally) trials and tribulations of its parent, Tyco International, have been both irrelevant to its strongly performing medical device business, Tyco Healthcare, and maddeningly distracting at the same time. But it has shaped the company's strategy, most notably in moving the company away from acquisitions as an engine of growth, forcing Tyco Healthcare to focus more on R&D and new product development.